Summary
The importance of tumor angiogenesis in the process of tumor growth and progression in solid tumors has been widely accepted. We have investigated the significance of tumor angiogenesis as a prognostic indicator in a retrospective study including 328 primary breast cancer patients. The postoperative survey demonstrated that the microvessel density (MVD) evaluated by immunocytochemical staining for factor VIII-related antigen is a potent prognostic indicator. The relapse-free survival (RFS) rate of patients with over 100 microvessels/mm2 in a microscopic field was significantly worse compared to that of patients with less than 100 microvessels/mm2 (p<0.00001). The significance of MVD was found in both node-negative and node-positve patients (p< 0.005 and p<0.01, respectively). Multivariate analysis confirmed that MVD is an independent prognostic indicator for RFS. In the background factor analysis, MVD was significantly correlated with the number of metastatic nodes (p<0.01). In addition, the immunocytochemical analysis for vascular endothelial growth factor (VEGF) demonstrated a close association between the increase in MVD and the expression of VEGF (p<0.001). VEGF status also was a significant prognostic indicator in univariate analysis for RFS (p<0.01). It was concluded that MVD is a potent prognostic indicator in primary breast cancer. Furthermore, it was also suggested that VEGF plays crucial roles in the promotion of angiogenesis in breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- MVD:
-
microvessel density
- VEGF:
-
vascular endothelial growth factor
References
Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4–6, 1990.
Bicknell R, Harris AL: Novel growth regulatory factors and tumor angiogenesis. Eur J Cancer 27: 781–784, 1991.
Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875–1887, 1992.
Horak ER, Leek R, Klenk N, Lejeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL: Angiogenesis, assessed by platelet/ endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340: 1120–1124, 1992.
Toi M, Kashitani J, Tominaga T: Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer, 55:371–374, 1993.
Gasparini G, Weidner N, Bevilacqua P, Maluta S, Dalla Palma P, Caffo O, Barbareschi M, Boracchi P, Marubini E, Pozza F: Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12:454–466, 1994.
Macchiarini P, Fontanini G, Hardin MJ, Sqartini F, Angeletti CA: Relation of neovasculature to metastasis of non-small-cell lung cancer. Lancet 340: 145–146, 1992.
Wakui S, Furusato M, Itoh T: Tumor angiogenesis in prostatic carcinoma with and without bone marrow metastasis: a morphometric study. J Pathol 168: 257–262, 1992.
Gasparini G, Weidner N, Maluta S, et al: Intratumoral microvessel density and p53 protein: Correlation with metastasis in head and neck squamous cell carcinoma. Int J Cancer 55:739–744, 1993.
Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis — correlation in invasive breast carcinoma. N Engl J Med 324:1–8, 1991.
Toi M, Tominaga T, Osaki A, Toge T: Role of epidermal growth factor receptor in primary breast cancer: results of a biochemical study and an immunocytochemical study. Breast Cancer Res Treat 29:51–58, 1994.
Ferrara N, Houck KA, Jakeman LB, Winer J, Leung DW: The vascular endothelial growth factor family of polypeptides. J Cell Biochem 47:211–218, 1991.
Cox DR: Analysis of Binary Data. Methuen, London, 1970.
Bosari S, Lee AK, DeLellis R, Wiley BD, Heatley GJ, Silverman ML: Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23: 755–761, 1992.
Sahin A, Sneige N, Singletary E, Ayala A: Tumor angiogenesis detected by factor VIII immunostaining in node negative breast carcinoma (NNBC): a possible predictor of distant metastasis. Lab Invest 66:17, 1992.
Fox SB, Leek RD, Smith K, Harris AL: Tumor angiogenesis in node-negative breast carcinomas — relationship to epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res Treat 29: 109–116, 1994.
Hall NR, Fish DE, Hunt N, Goldin RD, Guillou PJ, Monson JRT: Is the relatioship between angiogenesis and metastasis in breast cancer real? J Surg Oncol 23:755–761, 1992.
Van Hoef MEHM, Know WF, Dhesi SS, Howell A, Schor AM: Assessment of tumor vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer 29A:1141–1145, 1993.
Esch F, Baird A, Ling N, Ueno N, Hill F, Deneroy L, Klepper R, Gospadarowicz D, Bohlen P, Guillemin R: Primary structure of bovine basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF. Proc Natl Acad Sci USA 82:6507–6511, 1985.
Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, Usuki K, Takaku F, Risau W, Heldin C-H: Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 338:557–562, 1989.
Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, Comoglio PM: Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119:629–641, 1992.
Toi M, Harris AL, Bicknell R: Interleukin-4 is a potent mitogen for capillary endothelium. Biochem Biophys Res Commun 174:1287–1293, 1991.
Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permiability factor that promotes accumulation of ascites fluid. Science 219:983–985, 1983.
Ferrara N, Henzel WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161:851–858, 1989.
Toi M, Hoshina S, Takayanagi T, Tominaga T: Association of vascular endothelial growth factor expression with tumor angiogenesis and early response in primary breast cancer. Jpn J Cancer Res 85:1045–1049, 1994.
Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Berm H, Folkman J: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348:555–557, 1990.
Toi M, Yamamoto Y, Imazawa T, Takayanagi T, Akutsu K, Tominaga T: Antitumor effect of the angiogenesis inhibitor AGM-1470 and its combination effect with tamoxifen in DMBA induced mammary tumors in rats. Int J Oncol 3:525–528, 1993.
Kato T, Sato K, Kakinuma H, Matsuda Y: Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res 54:5143–5147, 1994.
Kim KJ, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362:841–844, 1993.
Kondo S, Asano M, Suzuki H: Significance of vascular endothelial growth factor / vascular permeability factor for solid tumor growth, and its inhibition by the antibody. Biochem Biophys Res Commun 194:1234–1241, 1993.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Toi, M., Inada, K., Suzuki, H. et al. Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Tr 36, 193–204 (1995). https://doi.org/10.1007/BF00666040
Issue Date:
DOI: https://doi.org/10.1007/BF00666040